Cingulate CINGW
NASDAQ CINGW
$0.01 +0.00 (+4.29%)
As of: Sep 9, 2026 · 11:16 AM EDT

Cingulate (CINGW) Share-based Compensation (2021 - 2026)

Cingulate's (CINGW) quarterly Share-based Compensation came in at $1.1 million in Q2 2026, up 176.63% on a YoY basis from $398839.0 in Q2 2025, and up 185.86% quarter-over-quarter from $385965.0 in Q4 2025.

Analysis

Cingulate (CINGW) Share-based Compensation (2021 - 2026) Analysis & Trends

Cingulate (CINGW) has reported Share-based Compensation for 6 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Share-based Compensation rose 176.63% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (up 176.63% YoY), and the FY2025 full-year result was $1.5 million, up 53.07% from the prior year.
  • Share-based Compensation improved to $1.1 million in Q2 2026 per CINGW's latest filing, from $385965.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.6 million in Q2 2024 and bottomed at $60349.0 in Q4 2024.
  • Historically, Share-based Compensation has averaged $695478.9 across 5 years, with a median of $812691.0 in 2024.
  • The sharpest annual moves came in 2022 and 2025: Share-based Compensation tumbled 90.12% in 2022, then soared 539.55% in 2025.
  • Over 5 years, Share-based Compensation stood at $206436.0 in 2022, then retreated by 25.13% to $154564.0 in 2023, then sank by 60.96% to $60349.0 in 2024, then jumped by 539.55% to $385965.0 in 2025, then surged by 185.86% to $1.1 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods registered $1.1 million, $385965.0, and $951677.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Johnson & Johnson 644.46 Bn 623.70 Bn 17.26 Bn -950.00 Mn
2 AbbVie 440.11 Bn 433.54 Bn 12.70 Bn 166.00 Mn
3 Merck 365.04 Bn 357.90 Bn 12.21 Bn 298.00 Mn
4 Novartis Ag 266.82 Bn 259.13 Bn 11.24 Bn -
5 Pfizer 159.14 Bn 147.45 Bn 10.94 Bn 249.00 Mn
6 Sanofi 52.47 Bn 45.09 Bn 10.79 Bn -
7 Revolution Medicines 44.26 Bn 44.26 Bn - 277.20 Mn
8 Incyte 25.32 Bn 20.79 Bn 1.57 Bn 67.26 Mn
9 United Therapeutics 21.46 Bn 18.80 Bn 683.80 Mn 19.00 Mn
10 Cingulate 100,214.03 100,214.03 - 1.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.10 Mn
Dec 31, 2025 385,965.00
Sep 30, 2025 951,677.00
Jun 30, 2025 398,839.00
Mar 31, 2025 357,649.00
Dec 31, 2024 60,349.00
Sep 30, 2024 812,691.00
Jun 30, 2024 1.59 Mn
Mar 31, 2024 164,575.00
Dec 31, 2023 154,564.00
Sep 30, 2023 1.45 Mn
Jun 30, 2023 1.35 Mn
Mar 31, 2023 204,479.00
Dec 31, 2022 206,436.00
Sep 30, 2022 881,112.00
Jun 30, 2022 883,801.00
Mar 31, 2022 866,284.00
Dec 31, 2021 2.09 Mn